Abstract

The limited time indorsed to face the COVID-19 emergency and large number of deaths across the globe, poses an unrelenting challenge to find apt therapeutic approaches. However, lead candidate selection to phase III trials of new chemical entity is a time-consuming procedure, and not feasible in pandemic, such as the one we are facing. Drug repositioning, an exploration of existing drug for new therapeutic use, could be an effective alternative as it allows fast-track estimation in phase II–III trials, or even forthright compassionate use. Although, drugs repurposed for COVID-19 pandemic are commercially available, yet the evaluation of their safety and efficacy is tiresome and painstaking. In absence of any specific treatment the easy alternatives such as over the counter products, phytotherapies and home remedies have been largely adopted for prophylaxis and therapy as well. In recent years, it has been demonstrated that several pharmaceutical excipients possess antiviral properties making them prospective candidates against SARS-CoV-2. This review highlights the mechanism of action of various antiviral excipients and their propensity to act against SARs-CoV2. Though, repurposing of pharmaceutical excipients against COVID-19 has the edge over therapeutic agents in terms of safety, cost and fast-track approval trial burdened, this hypothesis needs to be experimentally verified for COVID-19 patients.

摘要

面对 COVID-19 紧急情况和全球大量死亡的时间有限，对寻找合适的治疗方法提出了不懈的挑战。然而，新化学实体 III 期试验的主要候选人选择是一个耗时的过程，并且在大流行中不可行，例如我们面临的大流行。药物重新定位是对现有药物用于新治疗用途的探索，可能是一种有效的替代方案，因为它可以在 II-III 期试验中进行快速评估，甚至可以直接进行同情使用。尽管重新用于 COVID-19 大流行的药物可以在市场上买到，但对其安全性和有效性的评估是令人厌烦和艰苦的。在没有任何特定治疗的情况下，简单的替代品，例如非处方产品，植物疗法和家庭疗法也被广泛用于预防和治疗。近年来，已经证明几种药用辅料具有抗病毒特性，使其成为抗 SARS-CoV-2 的潜在候选药物。这篇综述强调了各种抗病毒辅料的作用机制及其对抗 SARs-CoV2 的倾向。尽管针对 COVID-19 的药用辅料再利用在安全性、成本和快速批准试验负担方面优于治疗剂，但这一假设需要对 COVID-19 患者进行实验验证。这篇综述强调了各种抗病毒辅料的作用机制及其对抗 SARs-CoV2 的倾向。尽管针对 COVID-19 的药用辅料再利用在安全性、成本和快速批准试验负担方面优于治疗剂，但这一假设需要对 COVID-19 患者进行实验验证。这篇综述强调了各种抗病毒辅料的作用机制及其对抗 SARs-CoV2 的倾向。尽管针对 COVID-19 的药用辅料再利用在安全性、成本和快速批准试验负担方面优于治疗剂，但这一假设需要对 COVID-19 患者进行实验验证。